



COMPANY OVERVIEW

Cerecor is an integrated biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare orphan diseases in Pediatrics and Neurology.

RECENT NEWS

Cerecor Receives Fast Track Designation from FDA for CERC-802 for the Treatment of Mannose-Phosphate Isomerase Deficiency

Aug 21 2019, 6:30 AM EDT

Cerecor Reports Second Quarter 2019 Results

Aug 8 2019, 4:05 PM EDT

STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	158.27m
Last Price	\$3.37
52-Week Range	\$2.71 - \$7.6499

09/20/2019 04:00 PM EDT

INVESTOR RELATIONS

ir@cerecor.com

MANAGEMENT TEAM

Joe Miller, CPA
Chief Financial Officer

Matthew V. Phillips
Chief Commercial Officer

Perry Calias, Ph.D.
Chief Scientific Officer | Head of R&D

James A. Harrell, Jr.
Executive Vice President, Marketing and External Communications

Patrick J. Crutcher
Chief Strategy Officer

CERECOR, INC.

540 Gaither Road
Suite 400
Rockville, MD 20850

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.